Samil Pharmaceutical Co., Ltd.   Report issue

For profit Phase 1 Phase 3 Phase 4
Founded: Seoul Korea, Republic of (1947)
Status: No NME R&D (1947)

Organization Overview

First Clinical Trial
2010
NCT01203540
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Samil Pharmaceutical Co., Ltd.

Active Ingredients

Drugs in Phase 4 Trials (6)

latanoprost (xalatan) (1 trial)

leucine (1 trial)

l-isoleucine (1 trial)

sodium chloride (1 trial)

spaglumic acid (1 trial)

valine (1 trial)

Drugs in Phase 3 Trials (1)

ksr-001 (1 trial)

Drugs in Phase 1 Trials (2)

atorvastatin (lipitor) (1 trial)

telmisartan (micardis) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Conjunctivitis (Phase 4)

Conjunctivitis, Allergic (Phase 4)

Dry Eye Syndromes (Phase 4)

Essential Hypertension (Phase 1)

Fibrosis (Phase 4)

Keratoconjunctivitis Sicca (Phase 4)

Liver Cirrhosis (Phase 4)

Liver Diseases (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 9